Clinical Trial Update: Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating VX15/2503 in patients with multiple sclerosis to assess safety, tolerability, and pharmacokinetics; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• VX15/2503

Snippet

Sponsor: Vaccinex Inc. | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED